术前使用双膦酸盐对全髋关节置换术结局的影响
基于全国行政索赔数据库的回顾性队列研究显示,在既往诊断髋骨关节炎合并骨质疏松/骨量减少的全髋关节置换术患者中,术前至少1年有双膦酸盐使用史者,术中及术后1年假体周围骨折(OR 1.39,95%CI 1.23,1.57)和翻修(OR 1.14,95%CI 1.04,1.25)风险显著高于术前未使用双膦酸盐的对照。无菌性松动、脱位、假体周围骨溶解及股骨或髋/骨盆应力性骨折发生率在双膦酸盐暴露组也较高,但未达统计学显著。
要点
- 术前使用双膦酸盐的全髋关节置换患者术中及术后1年假体周围骨折风险升高(OR 1.39)。
- 术前使用双膦酸盐者术后1年翻修风险升高(OR 1.14)。
- 无菌性松动、脱位、骨溶解及应力性骨折发生率较高但无统计学显著差异。
核心结论
- 全髋关节置换术前使用双膦酸盐与术中及术后1年并发症发生率较高相关。
- 这些发现可能影响对既往诊断骨质疏松/骨量减少并使用双膦酸盐的全髋关节置换患者的管理。
研究设计与样本
- 回顾性队列研究(证据等级3级),基于全国行政索赔数据库进行回顾性分析。
- 研究对象为既往诊断髋骨关节炎合并骨质疏松/骨量减少的全髋关节置换术患者。
- 双膦酸盐暴露组为全髋关节置换术前至少1年有双膦酸盐使用史的患者,对照组为术前未使用双膦酸盐者。
- 暴露组与对照组按年龄、性别和合并症以1:4比例匹配。
- 采用逻辑回归计算术中及术后1年并发症的比值比(OR)。
主要发现
- 双膦酸盐暴露组术中及术后1年假体周围骨折发生率显著高于对照组(OR 1.39,95%CI 1.23,1.57)。
- 双膦酸盐暴露组术中及术后1年翻修发生率显著高于对照组(OR 1.14,95%CI 1.04,1.25)。
- 双膦酸盐暴露组无菌性松动、脱位、假体周围骨溶解及股骨或髋/骨盆应力性骨折发生率高于对照组,但未达统计学显著。
关键数值与推荐
- 双膦酸盐暴露定义:全髋关节置换术前至少1年有双膦酸盐使用史。
- 匹配比例:暴露组与对照组按年龄、性别和合并症以1:4比例匹配。
- 主要结局:术中及术后1年并发症的比值比(OR)。
临床怎么用
- 原文结论指出术前使用双膦酸盐与全髋关节置换术中及术后1年并发症发生率较高相关,这些发现可能影响对既往诊断骨质疏松/骨量减少并使用双膦酸盐的全髋关节置换患者的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients undergoing total hip arthroplasty (THA) commonly have osteoporosis for which bisphosphonates (BPs) are Food and Drug Administration (FDA)-approved for treatment. Bisphosphonate use post-THA is associated with decreased periprosthetic bone loss or revisions, and increased longevity of implants. However, evidence is lacking for preoperative bisphosphonate use in THA recipients. This study investigated the association between bisphosphonate use pre-THA and outcomes. METHODS: A retrospective review of a national administrative claims database was conducted. Among THA recipients who had a prior diagnosis of hip osteoarthritis and osteoporosis/osteopenia, the treatment group (BP-exposed) consisted of patients who had a history of bisphosphonate use at least 1 year before THA; controls (BP-naive) comprised patients who did not have preoperative bisphosphonate use. The BP-exposed were matched to BP-naive in a 1:4 ratio by age, sex, and comorbidities. Logistic regressions were used to calculate the odds ratio for intraoperative and 1-year postoperative complications. RESULTS: The BP-exposed group had significantly higher rates of intraoperative and 1-year postoperative periprosthetic fractures (odds ratio (OR): 1.39, 95% confidence interval (CI): 1.23, 1.57) and revisions (OR: 1.14, 95% CI: 1.04, 1.25) compared with the BP-naive controls. BP-exposed also experienced higher rates of aseptic loosening, dislocation, periprosthetic osteolysis, and stress fracture of the femur or hip/pelvis compared to the BP-naive controls, but these values were not statistically significant. CONCLUSION: The use of bisphosphonates in THA patients preoperatively is associated with higher rates of intraoperative and 1-year postoperative complications. These findings may impact the management of patients undergoing THA who have a prior diagnosis of osteoporosis/osteopenia and use of bisphosphonates. LEVEL OF EVIDENCE: Retrospective Cohort Study (Level 3).
引用
- Jeong S, Lee JW, Boucher HR, et al. The Effect of Preoperative Bisphosphonate Use on Total Hip Arthroplasty Outcomes. J Arthroplasty. 2023. PMID: 37236285. doi:10.1016/j.arth.2023.05.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。